J&J scores Spravato trial win in high-risk depression. Will doctors and payers buy in?

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Sep 10, 2019 at 11:42 AM.

  1. #1 cafead, Sep 10, 2019 at 11:42 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,046
    Likes Received:
    3
    via Johnson & Johnson is attempting to change the antidepression market with its ketamine-derivative Spravato despite strict dosing requirements and a steep list price. New data in treating high-risk depression patients could help, but will physicians and payers come around?

    article source
     
    Quote

Reply to Thread